Alemtuzumab—A New Efficacy Benchmark in Relapsing–Remitting Multiple Sclerosis? 5.
Katrych O, Simone TM, Azad S, et al., Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes, CNS Neurol Disord Drug Targets, 2009;8:512–9.
6.
Jongen PJ, Sindic C, Carton H, et al., Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a, J Neurol, 2010;257:584–9.
7.
Rudick RA, Miller DM, Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment, CNS Drugs, 2008;22:827–39.
8.
IFNB Multiple sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group, Neurology, 1993;43:655–61.
9. PRISMS Study Group, Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis, Lancet, 1998;352:1498–504.
10. Cocco E, Marchi P, Sardu C, et al., Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis, Mult Scler, 2007;13:975–80.
11. Cohen JA, Barkhof F, Comi G, et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 2010;362:402–15.
12. Comi G, O'Connor P, Montalban X, et al., Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results, Mult Scler, 2010;16:197–207.
13. Galetta SL, Markowitz C, Lee AG, Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review, Arch Intern Med, 2002;162:2161–9.
14. Hartung HP, Gonsette R, Konig N, et al., Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial, Lancet, 2002;360:2018–25.
15. Hyde R, Bozic C, Belcher G, Utilization and safety of natalizumab in patients with relapsing multiple Sclerosis in the post-marketing setting, Congress of Neurology, Bangkok, Thailand, 24–30 October 2009.
16. Jacobs LD, Cookfair DL, Rudick RA, et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, 1996;39:285–94.
17. Johnson KP, Brooks BR, Cohen JA, et al., Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis, Neurology, 1995;45:1268–76.
18. Kappos L, Radue EW, O'Connor P, et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 2010;362:387–401.
19. Polman CH, O'Connor PW, Havrdova E, et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 2006;354:899–910.
20. Cadavid D, Cheriyan J, Skurnick J, et al., New acute and chronic black holes in patients with multiple sclerosis randomized to interferon beta-1b or glatiramer acetate, J Neurol Neurosurg Psychiatry, 2009;80:1337–43.
21. Comi G, Martinelli V, Rodegher M, et al., Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial, Lancet, 2009;374:1503–11.
22. Mikol DD, Barkhof F, Chang P, et al., Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study), Lancet Neurol, 2008;7:903–14.
23. O'Connor P, Filippi M, Arnason B, et al., 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study, Lancet Neurol, 2009;8:889–97.
24. Schwid SR, Thorpe J, Sharief M, et al., Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study, Arch Neurol,
2005;62:785–92.
25. Panitch H, Goodin D, Francis G, et al., Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial, J Neurol Sci, 2005;239:67–74.
26. Durelli L, Verdun E, Barbero P, et al., Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN), Lancet, 2002;359:1453–60.
27. Deisenhammer F, Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes, CNS Drugs, 2009;23: 379–96.
28. Goodin DS, Frohman EM, Hurwitz B, et al., Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology, 2007;68: 977–84.
29. Hartung HP, Munschauer F III, Schellekens H, Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference, Eur J Neurol, 2005;12:588–601.
30. Koch-Henriksen N, Sorensen PS, Bendtzen K, et al., The clinical effect of neutralizing antibodies against interferon- beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis, Mult Scler, 2009;15:601–5.
31. Pachner AR, Warth JD, Pace A, et al., Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study, Neurology, 2009;73:1493–1500.
32. van der Voort LF, Gilli F, Bertolotto A, et al., Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis, Arch Neurol, 2010;67:402–7.
33. Wiendl H, Toyka KV, Rieckmann P, et al., Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations, J Neurol, 2008;255:1449–63.
34. Belachew S, Phan-Ba R, Bartholome E, et al., Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing–remitting multiple sclerosis, Eur J Neurol, 2010 [Epub ahead of print].
35. Coyle PK, The role of natalizumab in the treatment of multiple sclerosis, Am J Manag Care, 2010;16:S164–70.
36. Kleinschmidt-DeMasters BK, Tyler KL, Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis, N Engl J Med, 2005;353:369–74.
37. Langer-Gould A, Atlas SW, Green AJ, et al., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab, N Engl J Med, 2005;353:375–81.
38. Yousry TA, Major EO, Ryschkewitsch C, et al., Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy, N Engl J Med, 2006;354:924–33.
39. Subramanyam M, Plavina T, Simon K, et al., Factors associated with anti-JCV antibody prevalence in a large cohort of natalizumab-treated MS patients. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. P138, Gothenberg, Sweden, 13–16 October 2010.
40. Ghalie RG, Edan G, Laurent M, et al., Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS, Neurology, 2002;59:909–13.
41. Martinelli V, Incidence of Acute Leukemia in Multiple Sclerosis Patients Treated with Mitoxandrone: A Multicentre Retrospective Italian Study. Abstract from the 61st Annual Meeting of the American Academy of Neurology (AAN), Seattle, WA, 2009.
42. Rammohan KW, Shoemaker J, Emerging multiple sclerosis oral therapies, Neurology, 2010;74(Suppl. 1):S47–53.
43. Patti F, Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence, Patient Prefer Adherence, 2010;4:1–9.
44. Turner AP, Williams RM, Sloan AP, et al., Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis, Rehabil Psychol, 2009;54:116–21.
45. Comi G, Pulizzi A, Rovaris M, et al., Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis, Lancet, 2008;371:2085–92.
46. Conway D, Cohen JA, Emerging Oral Therapies in Multiple Sclerosis, Curr Neurol Neurosci Rep, 2010;10(5):381–8.
47. Giovannoni G, Comi G, Cook S, et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, 2010;362:416–26.
48. Kappos L, Gold R, Miller DH, et al., Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo- controlled phase IIb study, Lancet, 2008;372:1463–72.
49. Marriott JJ, O'Connor PW, Emerging Therapies in Relapsing- Remitting Multiple Sclerosis, Rev Recent Clin Trials, 2010;5(3):179–88.
50. O'Connor P, Wolinsky J, Confavreux C, et al., A placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Gothenberg, Sweden, 13–16 October 2010.
51. Buttmann M, Treating multiple sclerosis with monoclonal antibodies: a 2010 update, Expert Rev Neurother, 2010;10: 791–809.
52. Demko S, Summers J, Keegan P, et al., FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia, Oncologist, 2008;13: 167–74.
53. Jones JL, Coles AJ, Spotlight on alemtuzumab, Int MS J, 2009;16:77–81.
54. Jones JL, Anderson JM, Phuah CL, et al., Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity, Brain, 2010;133(Pt 8):2232–47.
55. Xia MQ, Tone M, Packman L, et al., Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone, Eur J Immunol, 1991;21:1677–84.
56. Simpson BS, Coles AJ, Rationale for cytotoxic monoclonal antibodies in MS, Int MS J, 2007;14:48–56.
57. Gilleece MH, Dexter TM, Effect of Campath-1H antibody on human hematopoietic progenitors in vitro, Blood, 1993;82:807–12.
58. Hu Y, Turner MJ, Shields J, et al., Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model, Immunology, 2009;128:260–70.
59. Cox AL, Thompson SA, Jones JL, et al., Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis, Eur J Immunol, 2005;35:3332–42.
60. Thompson SA, Jones JL, Cox AL, et al., B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis, J Clin Immunol, 2010;30:99–105.
61. Coles AJ, Cox A, Le Page E, et al., The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, 2006;253:98–108.
62. The CAMMS223 Trial Investigators, Alemtuzumab versus interferon beta-1a in early multiple sclerosis, N Engl J Med, 2008;359:1786–801.
63. Coles A on behalf of the CAMMS223 Study Group, Alemtuzumab treatment benefit is durable: primary efficacy outcomes of CAMMS223 at 4 years Presented at the 25TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Dusseldorf, Germany, 9–12 September 2009, Poster P 890.
64. Khan O on Behalf of the CAMMS223 Study Group, Alemtuzumab Reduces Disease Progression in RRMS: Long-
US NEUROLOGY
89
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132